Posttranslational nitro-glycative modifications of albumin in Alzheimer's disease: implications in cytotoxicity and amyloid-β peptide aggregation.

Glycation and nitrotyrosination are pathological posttranslational modifications that make proteins prone to losing their physiological properties. Since both modifications are increased in Alzheimer's disease (AD) due to amyloid-β peptide (Aβ) accumulation, we have studied their effect on albumin, the most abundant protein in cerebrospinal fluid and blood. Brain and plasmatic levels of glycated and nitrated albumin were significantly higher in AD patients than in controls. In vitro turbidometry and electron microscopy analyses demonstrated that glycation and nitrotyrosination promote changes in albumin structure and biochemical properties. Glycated albumin was more resistant to proteolysis and less uptake by hepatoma cells occurred. Glycated albumin also reduced the osmolarity expected for a solution containing native albumin. Both glycation and nitrotyrosination turned albumin cytotoxic in a cell type-dependent manner for cerebral and vascular cells. Finally, of particular relevance to AD, these modified albumins were significantly less effective in avoiding Aβ aggregation than native albumin. In summary, nitrotyrosination and especially glycation alter albumin structural and biochemical properties, and these modifications might contribute for the progression of AD.

[1]  C. Colaco,et al.  A glycation connection , 1994, Nature.

[2]  N. Karmakar.  Interaction of transmural pressure and shear stress in the transport of albumin across the rabbit aortic wall. , 2001, Atherosclerosis.

[3]  J. Simpkins,et al.  Amyloid-β peptide fibrils induce nitro-oxidative stress in neuronal cells. , 2010, Journal of Alzheimer's disease : JAD.

[4]  M. Noroozian,et al.  Nitric oxide and peroxynitrite serum levels in Parkinson's disease: correlation of oxidative stress and the severity of the disease. , 2013, European review for medical and pharmacological sciences.

[5]  Visith Thongboonkerd,et al.  Proteomic identification of nitrated proteins in Alzheimer's disease brain , 2003, Journal of neurochemistry.

[6]  S. Oliet,et al.  Osmoreceptors in the central nervous system. , 1997, Annual review of physiology.

[7]  L. Tjernberg,et al.  Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues. , 1999, The Journal of biological chemistry.

[8]  L. Vázquez-Moreno,et al.  Characterization of Bovine Serum Albumin Glycated with Glucose, Galactose and Lactose , 2022 .

[9]  R. Bucala,et al.  Advanced glycation end products contribute to amyloidosis in Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Andreu,et al.  Lack of oestrogen protection in amyloid-mediated endothelial damage due to protein nitrotyrosination. , 2005, Brain : a journal of neurology.

[11]  P. Brick,et al.  Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites , 1998, Nature Structural Biology.

[12]  A. Venn,et al.  Methylglyoxal, cognitive function and cerebral atrophy in older people. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.

[13]  S. Paek,et al.  Induction of Neuronal Death by Microglial AGE-Albumin: Implications for Alzheimer’s Disease , 2012, PloS one.

[14]  Xudong Huang,et al.  The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. , 1999, Biochemistry.

[15]  A. Cerami,et al.  Nonenzymatic Glycosylation Reduces the Susceptibility of Fibrin to Degradation by Plasmin , 1983, Diabetes.

[16]  K. Boje,et al.  Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death , 1992, Brain Research.

[17]  M. F. Weiss,et al.  Cellular oxidant stress and advanced glycation endproducts of albumin: caveats of the dichlorofluorescein assay. , 2002, Archives of Biochemistry and Biophysics.

[18]  B. Frangione,et al.  Brain amyloid in normal aging and cerebral amyloid angiopathy is antigenically related to Alzheimer's disease beta-protein. , 1987, The American journal of pathology.

[19]  K. Calman,et al.  INCREASED VASCULAR PERMEABILITY: A MAJOR CAUSE OF HYPOALBUMINAEMIA IN DISEASE AND INJURY , 1985, The Lancet.

[20]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Hoffenberg,et al.  Regulation of Albumin Synthesis and Catabolism by Alteration of Dietary Protein , 1968, Nature.

[22]  A. Del Corso,et al.  Chaperone-like features of bovine serum albumin: a comparison with alpha-crystallin. , 2005, Cellular and molecular life sciences : CMLS.

[23]  Hailing Li,et al.  Amyloid beta–heme peroxidase promoted protein nitrotyrosination: relevance to widespread protein nitration in Alzheimer’s disease , 2011, JBIC Journal of Biological Inorganic Chemistry.

[24]  Paul J Thornalley,et al.  Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and intrinsic fluorescence. , 2002, The Biochemical journal.

[25]  G. Thomas,et al.  An analog of the human albumin N-terminus (Asp-Ala-His-Lys) prevents formation of copper-induced reactive oxygen species. , 2001, Biochemical and biophysical research communications.

[26]  M. Dadlez,et al.  The binding constant for amyloid Abeta40 peptide interaction with human serum albumin. , 2007, Biochemical and biophysical research communications.

[27]  J. Beckman,et al.  Reactions between nitric oxide, superoxide, and peroxynitrite: footprints of peroxynitrite in vivo. , 1995, Advances in pharmacology.

[28]  K. Davies,et al.  Protein turnover by the proteasome in aging and disease. , 2002, Free radical biology & medicine.

[29]  M. Okada,et al.  Exploring mechanisms of diabetes-related macrovascular complications: role of methylglyoxal, a metabolite of glucose on regulation of vascular contractility. , 2012, Journal of pharmacological sciences.

[30]  B. Friguet,et al.  Protein Degradation by the Proteasome and Its Implications in Aging , 2000, Annals of the New York Academy of Sciences.

[31]  V. Monnier,et al.  Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. , 1981, Science.

[32]  J. H. Viles,et al.  The cellular prion protein traps Alzheimer's Aβ in an oligomeric form and disassembles amyloid fibers , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  C. Harrington,et al.  Alzheimer's disease. A glycation connection. , 1994, Nature.

[34]  A. Hipkiss,et al.  Frontiers in Aging Neuroscience Aging Neuroscience Review Article Increased Mitochondrial Dysfunction and Altered Protein Accumulation – Association with Aging , 2022 .

[35]  Jordi Villà-Freixa,et al.  Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation. , 2009, Brain : a journal of neurology.

[36]  S. Era,et al.  Age-related change in redox state of human serum albumin. , 1994, Biochimica et biophysica acta.

[37]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  W. Markesbery,et al.  Proteomic identification of nitrated brain proteins in early Alzheimer’s disease inferior parietal lobule , 2009, Journal of cellular and molecular medicine.

[39]  N. Durany,et al.  Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus , 2010, Neurobiology of Disease.

[40]  K. Gevaert,et al.  Improved tandem mass spectrometric characterization of 3-nitrotyrosine sites in peptides. , 2006, Rapid communications in mass spectrometry : RCM.

[41]  Y. Chernoff,et al.  Identification of PrP sequences essential for the interaction between the PrP polymers and Aβ peptide in a yeast-based assay , 2013, Prion.

[42]  E. Masliah,et al.  nNOS Expressing Neurons in the Entorhinal Cortex and Hippocampus Are Affected in Patients with Alzheimer's Disease , 1998, Experimental Neurology.

[43]  W. Markesbery,et al.  Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[44]  P. White,et al.  Enhanced extravasation, stability and in vivo cardiac gene silencing via in situ siRNA-albumin conjugation. , 2012, Molecular pharmaceutics.

[45]  H. Zoellner,et al.  The anti-apoptotic activity of albumin for endothelium is inhibited by advanced glycation end products restricting intramolecular movement , 2009, Cellular & Molecular Biology Letters.

[46]  T. Arendt,et al.  Methylglyoxal, Glyoxal, and Their Detoxification in Alzheimer's Disease , 2005, Annals of the New York Academy of Sciences.

[47]  F. X. Guix,et al.  The physiology and pathophysiology of nitric oxide in the brain , 2005, Progress in Neurobiology.

[48]  A. Cerami,et al.  Glucose and aging. , 1987, Scientific American.

[49]  B. Hyman,et al.  Amyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma* , 1996, The Journal of Biological Chemistry.

[50]  U. Mura,et al.  Chaperone-like features of bovine serum albumin: a comparison with α-crystallin , 2005, Cellular and Molecular Life Sciences CMLS.

[51]  Joseph S. Beckman,et al.  Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease , 1997, The Journal of Neuroscience.

[52]  J. H. Viles,et al.  Human Serum Albumin Can Regulate Amyloid-β Peptide Fiber Growth in the Brain Interstitium , 2012, The Journal of Biological Chemistry.

[53]  K. Dildar,et al.  Serum Nitrosative Stress Levels Are Increased in Alzheimer Disease but Not in Vascular Dementia , 2010, Alzheimer disease and associated disorders.

[54]  S. Paek,et al.  Human Microglial Cells Synthesize Albumin in Brain , 2008, PloS one.

[55]  E. Kallee,et al.  Comparative studies on the half-life of I 131-labeled albumins and nonradioactive human serum albumin in a case of analbuminemia. , 1959, The Journal of clinical investigation.

[56]  N. Roy,et al.  Current perspectives on potential role of albumin in neuroprotection , 2011, Reviews in the neurosciences.

[57]  B. Shapiro,et al.  Release of ovoperoxidase from sea urchin eggs hardens the fertilization membrane with tyrosine crosslinks. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[58]  R. Elosua,et al.  Trends in cardiovascular risk factor prevalence (1995-2000-2005) in northeastern Spain , 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[59]  V. Monnier,et al.  Effects of Advanced Glycation End Product Modification on Proximal Tubule Epithelial Cell Processing of Albumin , 2007, American Journal of Nephrology.

[60]  Alberto Lleó,et al.  Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease , 2012, Acta Neuropathologica.